Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Survivin Peptide-HLA-A*02:01 Complex
- Molecular classification
- Peptide-MHC Complex, MHC Class I molecule, Tumor-associated antigen
01
Overview
The Survivin peptide-HLA-A*02:01 complex is a molecular structure formed by the binding of a peptide derived from the human protein Survivin (also known as BIRC5) to the HLA-A*02:01 major histocompatibility complex (MHC) class I molecule. This complex is recognized by cytotoxic T lymphocytes (CTLs), making it highly relevant for cancer immunotherapy and immune monitoring applications. It represents a clinically significant target structure enabling selective recognition and destruction of cancer cells by the immune system. Its use spans basic research tools through translational applications such as cancer vaccines and engineered cellular therapies targeting malignancies overexpressing survivin while sparing normal tissues due to its restricted expression profile outside tumors.
- Other names
- BIRC5/Human Baculoviral IAP repeat-containing proteinSurvivin-HLA-A*02:01LTLGEFLKL-HLA-A*02:01LMLGEFLKL-HLA-A*02:01ELTLGEFLKL-HLA-A*02:01ELMLGEFLKL-HLA-A*02:01
02
Mechanism of action
Stimulates CD8+ T cell response, leading to targeted killing of cancer cells
03
Biological functions
Antigen presentationT cell activationImmune responseTumor recognition
04
Disease associations
CancerTumor immunology
05
Safety considerations
Potential for off-target toxicityImmune-related adverse eventsTumor escape mechanismsLimited efficacy in HLA-A*02:01 negative individuals
06
Biomarkers
HLA-A*02:01 statusSurvivin expression levelsPresence of Survivin-specific CTLs
Beyond the preview
Go deeper on Survivin Peptide-HLA-A*02:01 Complex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Survivin Peptide-HLA-A*02:01 Complex.